Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

PMID: 21972212
PMCID: PMC3186296
DOI: 10.3324/haematol.2011.048991

Comment

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

Massimo Breccia et al. Haematologica. 2011 Oct.

. 2011 Oct;96(10):e41-2.

doi: 10.3324/haematol.2011.048991.

Authors

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

PMID: 21972212
PMCID: PMC3186296
DOI: 10.3324/haematol.2011.048991

No abstract available

PubMed Disclaimer

Comment on

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M. Della Porta MG, et al. Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6. Haematologica. 2011. PMID: 21134982 Free PMC article.
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Cazzola M. Cazzola M. Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023. Haematologica. 2011. PMID: 21357714 Free PMC article. No abstract available.

Cited by

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.
Zeidan AM, Komrokji RS. Zeidan AM, et al. Curr Hematol Malig Rep. 2013 Dec;8(4):351-60. doi: 10.1007/s11899-013-0172-3. Curr Hematol Malig Rep. 2013. PMID: 23979829 Free PMC article. Review.
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.
Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U. Zipperer E, et al. Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24. Haematologica. 2014. PMID: 24463211 Free PMC article. No abstract available.
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.
Kubasch AS, Platzbecker U. Kubasch AS, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):418-425. doi: 10.1182/hematology.2020000126. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275703 Free PMC article.
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Saussele S, et al. Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27. Blood. 2015. PMID: 25918346 Free PMC article. Clinical Trial.
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.
Breccia M, Salaroli A, Loglisci G, Finsinger P, Serrao A, Alimena G. Breccia M, et al. Haematologica. 2012 Feb;97(2):e2. doi: 10.3324/haematol.2011.059808. Haematologica. 2012. PMID: 22298822 Free PMC article. No abstract available.

References

1. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodys-plastic syndrome. Haematologica. 2011;96(3):441–9. - PMC - PubMed
1. Cazzola M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2011;96(3):349–52. - PMC - PubMed
1. Breccia M, Federico V, Latagliata R, Mercanti C, D’Elia GM, Cannella L, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35(2):159–62. - PubMed
1. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(33):3503–10. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

Authors

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical